31 July 2020
EMA/CHMP/358236/2020
EMEA/H/C/004412

Public statement

Duzallo

Withdrawal of the marketing authorisation in the European Union

On 31 July 2020, the European Commission withdrew the marketing authorisation for Duzallo (allopurinol / lesinurad) in the European Union (EU). The withdrawal was at the request of the marketing authorisation holder, Grunenthal GmbH, which notified the European Commission of its decision not to market the product in the EU for commercial reasons.

Duzallo was granted marketing authorisation in the EU on 23 August 2018 for gout. The marketing authorisation was initially valid for a 5-year period. The product had not been marketed in the EU since 2018.

The European Public Assessment Report (EPAR) for Duzallo will be updated to indicate that the marketing authorisation is no longer valid.

Official address Domenico Scarlattilaan 6 ● 1083 HS Amsterdam ● The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000 An agency of the European Union